DNA-Technology at the Women’s Health Leadership Forum: Advancing Personalized Medicine for Women Health

Women’s Health Leadership Forum took place in Dubai as part of Medlab Middle East 2025, bringing together experts to discuss the latest advancements in women’s healthcare.

DNA-Technology, as the headline sponsor of the Forum and a gold sponsor of Medlab Middle East, played a key role in shaping the conversation around personalized medicine and tailored diagnostics for women.

A highlight of the event was an engaging plenary session focused on personalized medicine—a rapidly evolving approach in healthcare that aims to identify predispositions to diseases, reduce health risks, and provide individualized treatment strategies. One of the key topics discussed was the importance of advanced molecular diagnostics in improving women’s health outcomes.

The session featured distinguished medical leaders and industry experts, including:
 - Dr. Kadria Sayed, Consultant Anatomical and Clinical Pathology - Chief of Pathology & Laboratory Department, American Hospital, UAE
 - Dr. Ritu Nayar Professor of Pathology and Medical Education, Northwestern University, Feinberg School of Medicine; Executive Vice Chair, Department of Pathology; Medical Director, Cytopathology Laboratory, Northwestern Memorial Hospital, Chicago, Illinois, USA
 - Dr. Rania Seliem, Head of Pathology, Rashid Hospital Dubai Academic Health Corporation, UAE
 - Jacqueline Karachi, Associate Director, Marketing, Qiagen
 - Professor Ekaterina Voroshilina, Head of Medical Microbiology and Laboratory Diagnostics, DNA-Technology
 - Sarah Barakat, Government Affairs and Market Access, Merck Gulf, UAE
 - Dr. Samarha Faik, Chief of Obstetrics and Gynecology, American Hospital, UAE

As part of the discussion, Professor Ekaterina Voroshilina presented on “New Solutions for Overcoming Reproductive Problems in Women.” She highlighted the role of innovative PCR-based diagnostics in addressing common and serious gynecological conditions, focusing on two key solutions developed by DNA-Technology:

 - Femoflor®️ 16, a multiplex PCR test for assessing vaginal microbiota, helps diagnose bacterial vaginosis, candidiasis, and other dysbiosis-related conditions by detecting and quantifying 16 key bacterial and fungal species. By providing a comprehensive analysis of vaginal flora, Femoflor®️ 16 enables early  intervention and personalized treatment strategies, reducing the risk of complications in reproductive health.
• HPV-Quant 21, an advanced quantitative PCR test, is designed for the detection and genotyping of 21 high-risk and low-risk HPV types. Unlike traditional HPV tests, HPV-Quant®️ 21 not only identifies the presence of the virus but also quantifies the viral load, allowing for better risk stratification in cervical cancer prevention and more precise treatment decisions.

With Femoflor®️ 16 and HPV-Quant 21, DNA-Technology is driving innovation in women’s health diagnostics, empowering healthcare professionals with highly accurate and actionable data. These solutions are helping to shift the paradigm from reactive treatment to early detection, prevention, and personalized care.

As a leader in molecular diagnostics, DNA-Technology  remains committed to advancing women’s health through cutting-edge solutions and strategic collaborations with global healthcare professionals. Our participation in the Women’s Health Leadership Forum reinforces our dedication to innovation and excellence in personalized medicine.

The forum has received extensive media coverage, further emphasizing its significance in the field of women’s health:
MedEdge MEA Coverage

One Ville News Article

Additionally, video records of Professor Ekaterina Voroshilina presentation and plenary session at the Women’s Health Leadership Forum, are available here:
View E.  Voroshilina presentation
View plenary session